Get 40% Off
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list

Roche to acquire Carmot Therapeutics in $3.1 billion deal

Published 04/12/2023, 13:56
Updated 04/12/2023, 13:56
© Reuters.

Biotechnology giant Roche (RHHBY (OTC:RHHBY)) will acquire obesity drug maker Carmot Therapeutics in a $3.1 billion deal, it was announced Monday.

The agreement will see Roche pay $2.7 billion for Carmot, with the potential for a further $400 million in milestone payments. The deal is expected to close in the first quarter of 2024.

Carmot will join Roche's pharmaceutical division, with the company stating it believes the deal will help it further develop its programs. Carmot's current pipeline includes subcutaneous and oral incretins with the potential to treat obesity in patients with and without diabetes.

"The obesity epidemic is a worldwide crisis and only continues to worsen. By 2035, it is estimated that nearly half the world's population will be overweight or obese," said Tim Kutzkey, Chair of Carmot's Board of Directors.

"A health problem of this magnitude requires significant commitment and resources to address, and we believe that patients will be best served with Carmot's pipeline backed by the drug development expertise, extensive resources and worldwide reach of Roche."

Roche's Switzerland-listed shares are up 2% so far on Monday.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.